Evaluation of the effect of choline-stabilized orthosilicic acid (ch-OSA®) in patients with tennis elbow

ISRCTN ISRCTN12631735
DOI https://doi.org/10.1186/ISRCTN12631735
Secondary identifying numbers 17/3
Submission date
04/09/2020
Registration date
15/09/2020
Last edited
25/08/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Lateral epicondylitis, also known as "Tennis Elbow", is the most common overuse syndrome in the elbow. Most of the traditional treatments such as anti-inflammatory medications, rest, physical therapy and corticosteroid injections do not alter the tendon's poor healing properties.
Choline-stabilized orthosilicic acid has been reported to improve the symptoms of soft tissue injuries (i.e. pain relief and improved mobility).
This study will investigate whether choline-stabilized orthosilicic acid can relieve the symptoms of epicondylitis.

Who can participate?
Adults between the ages of 18 and 70 with epicondylitis symptoms lasting 12 weeks or longer

What does the study involve?
Patients are randomly allocated to either receive choline-stabilized orthosilicic acid or placebo (dummy capsule). All patients will be instructed to take two capsules daily for 20 weeks. Assessments will be done at the screening visit, inclusion to the study, and after 5, 10, 15 and 20 weeks of treatment. If necessary, rescue medication in the form of paracetamol (up to 4 g/day) is permitted up to 48 hours before the baseline visit and other study visits.

What are the possible benefits and risks of participating?
Choline-stabilized orthosilicic acid may support soft tissue healing. Considering the available information about choline-stabilized orthosilicic acid, there are no foreseeable risks to human health when used as instructed.

Where is the study run from?
Bio Minerals NV (Belgium)

When is the study starting and how long is it expected to run for?
March 2017 to January 2023

Who is funding the study?
Bio Minerals NV (Belgium)

Who is the main contact?
Prof. Dr Alexander Van Tongel
alexander.vantongel@ugent.be

Contact information

Mr Mattias Bonnarens
Public

Zenderstraat 12
Destelbergen
9070
Belgium

ORCiD logoORCID ID 0000-0001-8177-1138
Phone +32 (0)9 3351327
Email mattias.bonnarens@biominerals.be

Study information

Study designMulti-center double-blind randomized placebo-controlled phase III study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleA randomized, double-blind placebo-controlled study to assess the effect of choline-stabilized orthosilicic acid on lateral epicondylitis
Study objectivesThe aim of the study is to evaluate the effect of oral intake of choline-stabilized orthosilicic acid over a 20 week period on the symptoms of lateral epicondylitis.
Ethics approval(s)Approved 05/03/2018, Central ethical committee: Commission for Medical Ethics/Commissie voor Medische Ethiek (UZ Gent, entrance 75, route 7522, Corneel Heymanslaan 10, 9000 Gent, Belgium; +32 (0)9 332 49 62; ethisch.comite@uzgent.be), ref: not provided
Health condition(s) or problem(s) studiedLateral epicondylitis
InterventionParticipants are randomized to either the placebo or active treatment group (choline-stabilized orthosilicic acid) using block randomization in a ratio of 1:1.

All participants will be instructed to take daily for 20 weeks, two capsules orally of either placebo (520 mg microcrystalline cellulose beadlets), or the active ingredient (520 mg beadlets containing 5 mg of silicon and 100 mg of choline in the form of choline-stabilized orthosilicic acid). The trial starts with a screening visit and a wash-out period during which the use of lateral epiconylititis treatment is not permitted.

Assessments will be done respectively at inclusion (baseline), and after 5, 10, 15 and 20 weeks of treatment. If necessary, rescue medication under the form of paracetamol (up to 4g/day) is permitted up to 48 hours before the baseline visit and other study visits.
Intervention typeSupplement
Primary outcome measureElbow pain severity measured using a visual analog scale (VAS, 100mm) at baseline and 20 weeks
Secondary outcome measures1. Disabilities of the Arm, Shoulder and Hand (DASH) score measured using DASH questionnaire at baseline, 5, 10, 15 and 20 weeks
2. Patient-Rated Tennis Elbow Evaluation (PRTEE) score measured using PRTEE questionnaire at baseline, 5, 10, 15 and 20 weeks
3. Elbow pain severity measured using a visual analog scale (VAS, 100, mm) at baseline, 5, 10 and 15 weeks
4. Pain-free grip strengths and maximum grip strength measured using a GRIP-D meter at baseline, 5, 10, 15 and 20 weeks
5. Echogenicity and vascularity measured by color Doppler sonography at screening or baseline, 10 and 20 weeks
6. Use of paracetamol as rescue medication measured using patient report at baseline, 5, 10, 15 and 20 weeks
7. Biomarkers of collagen metabolism measured using serum and urine samples at baseline, 10 and 20 weeks
8. Serum markers of inflammation measured using serum samples at baseline, 10 and 20 weeks
Overall study start date28/03/2017
Completion date31/01/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants130
Total final enrolment148
Key inclusion criteria1. Provision of written informed consent
2. Males, pre-menopausal females, peri- or post-menopausal females currently taking hormone replacement therapy between the ages of 18 and 70 years old
3. Females must use an approved form of birth control
4. Painful, chronic tendinopathy present in lateral elbow in one arm. The baseline elbow is > 40 on a scale of 100 mm (VAS: "0" representing no pain and "100" worst imaginable pain) during elbow extension and resisted wrist extension (Cozen's test)
5. The epicondylitis symptoms lasting at least 12 weeks or longer
6. A history of at least two periods of elbow pain lasting >10 days
7. BMI between 18.5 and 35 kg/m²
8. Participant must continue his/her normal physical activities during the study i.e. there should be no change in physical activity after the screening visit
Key exclusion criteria1. Unable to understand the study procedures and/or not wishing to participate in one of the subsequent therapeutic intervention protocols
2. Poor general health interfering with compliance or assessment
3. Unlikely to co-operate fully in the study
4.. Participating in another clinical trial in the last 90 days
5. Pregnancy or breastfeeding
6. Radiological examinations show abnormalities such as arthritis and inflammatory arthropathy of the elbow joint in the target arm
7. Participants with a history of trauma, ligament damage, fracture, tumor or surgery of the elbow joint in the target arm
8. Proven and current symptomatic peripheral nerve entrapment syndrome
9. Proven and current symptomatic cervical facet arthrosis: C5-C6/C6-C7
10. Proven and current symptomatic radiculopathy
11. Fibromyalgia, chronic fatigue syndrome
12. New physical activity i.e. physical activity which was not present prior to the screening visit
13. Recent or current alcohol abuse
14. Participants with documented, active infection diseases such as HIV or hepatitis B/C
15. Clinically significant medical abnormalities which would make the subject unsuitable for the study, as judged by the investigator, such as mental disorders
16. Participant has documented renal failure, history of stroke, myocardial infarct or cancer
17. Concomitant and previous medication
17.1. Less than 6 months between the local treatment of epicondylitis with platelet-rich plasma (PRP), autologous conditioned plasma (ACP) or autologous whole blood (AWB) injections and inclusions in the study
17.2. Less than 3 months between the local treatment of epicondylitis with shockwaves or steroid injections and inclusion in the study
17.3. Less than 6 weeks between the local treatment of epicondylitis with botulinum toxin, glycosaminoglycan polysulfate (hyaluronic acid) or dextrose injections and inclusion in the study
17.4. Less than 15 days between the treatment and inclusion in the study: systemic or topical use of NSAIDs and analgesics, different from paracetamol; systemic opoids and corticosteroids; treatment for epicondylitis with acupuncture or physiotherapy
17.5. Less than 3 months between supplementation with food supplements containing horsetail extract, bamboo extract, silicic acid or silanol derivatives and inclusion in the study
Date of first enrolment24/05/2018
Date of final enrolment31/08/2022

Locations

Countries of recruitment

  • Belgium

Study participating centres

Ghent University Hospital
Department of Physical and Rehabilitation Medicine
Corneel Heymanslaan 10
Ghent
9000
Belgium
Ghent University Hospital
Department of Orthopaedic Surgery and Traumatology
Corneel Heymanslaan 10
Ghent
9000
Belgium
AZ Monica
Department of Orthopaedic Surgery
Stevenslei 20
Deurne
2100
Belgium
Ziekenhuis Oost-Limburg
Schiepse Bos 6
Genk
3600
Belgium
AZ Sint-Lucas Gent
Department of Orthopaedic Surgery
Groenebriel 1
Ghent
9000
Belgium
AZ Sint-Lucas Brugge
Department of Orthopaedic Surgery
Sint-Lucaslaan 29
Brugge
8310
Belgium
AZ Sint-Lucas Brugge
Revalidatiecentrum
Sint-Lucaslaan 29
Brugge
8310
Belgium
AZ Sint-Jan Brugge
Department of Orthopaedic Surgery
Ruddershove 10
Brugge
8000
Belgium
UZ Antwerpen
Department Physical Medicine and Rehabilitation
Wilrijkstraat 10
Edegem-Antwerp
2650
Belgium
Sportpraktijk De Merode
De Merodelei 197
Turnhout
2300
Belgium
Sportartsenpraktijk
Michel Wittockstraat 21/001
Wilrijk
2610
Belgium

Sponsor information

Bio Minerals NV
Industry

Zenderstraat 12
Destelbergen
9070
Belgium

Phone +32 (0) 9 228 20 00
Email ine.decock@biominerals.be

Funders

Funder type

Industry

Bio Minerals NV

No information available

Results and Publications

Intention to publish date31/12/2023
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination plan1. Planned publication in a high-impact peer-reviewed journal.
2. Participants can contact the principal investigator to get access to their raw data and for discussion.
3. No additional files will be available.
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date.

Editorial Notes

25/08/2022: The following changes were made to the trial record:
1. The contact was updated.
2. The total final enrolment was added.
08/03/2022: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/03/2022 to 31/08/2022.
2. The overall trial end date was changed from 31/08/2022 to 31/01/2023 and the plain English summary has been updated to reflect this change.
06/09/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/09/2021 to 30/03/2022.
2. The overall trial end date was changed from 31/01/2022 to 31/08/2022.
3. The intention to publish date was changed from 30/06/2022 to 31/12/2023.
11/01/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 31/01/2021 to 30/09/2021.
2. The overall trial end date was changed from 30/06/2021 to 31/01/2022.
3. The intention to publish date was changed from 31/12/2021 to 30/06/2022.
14/09/2020: Trial's existence confirmed by Commission for Medical Ethics, UZ Gent.